Trial · NCT03226067
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Percent Change in Serum GGT. | Baseline to week 24 (visit 7) | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Serum GGT | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | U/L | MEAN |
| SECONDARY | Percent Change in Serum GGT | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Percent Change in Serum ALP | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Serum ALP | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | U/L | MEAN |
| SECONDARY | Absolute Change in Serum Conjugated Bilirubin. | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | μmol/L | MEAN |
| SECONDARY | Percent Change in Serum Conjugated Bilirubin. | From baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Serum Total Bilirubin. | from baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | μmol/L | MEAN |
| SECONDARY | Percent Change in Serum Total Bilirubin. | from baseline to Weeks 2, 6, 12, 18 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Liver Stiffness as Assessed by Transient Elastography (FibroScan® or Similar Technology). | From baseline to Week 24, in patients with values at baseline and Week 24. | Number of subjects analyzed in the Intent to Treat population who have evaluable results | kPa | MEAN |
| SECONDARY | Percent Change in Liver Stiffness as Assessed by Transient Elastography (FibroScan® or Similar Technology). | From baseline to Week 24, in patients with values at baseline and Week 24. | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Percent Change in Serum Levels of Collagen Fragments Indicative of Collagen Formation and Degradation. | From baseline to Weeks 12 and 24. | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Liver Stiffness as Assessed by Transient Elastography by Subgroup (FibroScan® or Similar Technology). | From baseline to Week 24, in patients with values at baseline and Week 24. | Number of subjects analyzed in the Intent to Treat population who have evaluable results | kPa | MEAN |
| SECONDARY | Percent Change in Liver Stiffness as Assessed by Transient Elastography by Subgroup (FibroScan® or Similar Technology). | From baseline to Week 24, in patients with values at baseline and Week 24. | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in Pruritis Visual Analogue Scale (VAS) Scores | From baseline to Weeks 12 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | score on a scale | MEAN |
| SECONDARY | Percent Change in Pruritis Visual Analogue Scale (VAS) Scores | From baseline to Weeks 12 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
| SECONDARY | Absolute Change in PBC-40 (Primary Biliary Cholongitis) Domain Scores | From baseline to Weeks 12 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | score on a scale | MEAN |
| SECONDARY | Percent Change in PBC-40 (Primary Biliary Cholongitis) Domain Scores | From baseline to Weeks 12 and 24 | Number of subjects analyzed in the Intent to Treat population who have evaluable results | percent change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03226067/outcomes